TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02583802
Drug: Shengmai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
Study: NCT02607254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
Study: NCT04000451
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
Study: NCT02681055
Drug: MN-001
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
Study: NCT00127530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill, twice a day (b.i.d.)
Study: NCT04044209
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
Study: NCT00831441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, twice daily, until study end
Study: NCT03956017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
Study: NCT03975283
Drug: Exparel 266 MG Per 20 ML Injection
Normalized name: Exparel 266 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
Study: NCT00724282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth daily at bedtime for 9 days
Study: NCT00960934
Drug: MK-5442
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
Study: NCT00960934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched oral placebo to MK-5442
Study: NCT00442013
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
Study: NCT01030458
Drug: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
Study: NCT00503360
Drug: SAD448
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00414700
Drug: ChondroCelect implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm².
Study: NCT03959865
Drug: Long-acting GLP-1RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
Study: NCT03959865
Drug: Short-acting GLP-1RA
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
Study: NCT03959865
Drug: Exendin-based GLP-1RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
Study: NCT03959865
Drug: Fixed ratio BI/GLP-1RA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
Study: NCT03959865
Drug: Flexible BI/GLP-1RA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
Study: NCT00071487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Study: NCT02099838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
Study: NCT03049046
Drug: CC100
Normalized name: CENTRAL LINE DRESSING KIT M#BSIPICC1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic caffeic acid phenethylester
Study: NCT03049046
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent
Study: NCT00370162
Drug: lactoserum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01369342
Drug: Group 1: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=intravenous use, in a single dose.
Study: NCT04586114
Drug: Corticosteroids and Derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any systemic corticosteroid treatment administrated during ICU stay
Study: NCT00620477
Drug: injection in the knee joint with 20 ml of chirocaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection in the knee joint with 20 ml of chirocaine 0.125%
Study: NCT00620477
Drug: injection in the knee joint with 20 ml of physiological fluid
Normalized name: BOS TAURUS KNEE JOINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection in the knee joint with 20 ml of physiological fluid
Study: NCT01840423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01840423
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: entacapone + levodopa/carbidopa
Study: NCT01479920
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study: NCT01056224
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
Study: NCT04093518
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Study: NCT04093518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Study: NCT02529293
Drug: BioChaperone Lispro U-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BioChaperone Lispro U-100
Study: NCT02529293
Drug: BioChaperone Lispro U-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BioChaperone Lispro U-200
Study: NCT01782989
Drug: ORACEA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORACEA® (40mg doxycycline) capsule daily for 24 months
Study: NCT01782989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for 24 months
Study: NCT04112147
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 12-week of 100mg BID Antroquinonol placebo
Study: NCT00324623
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00283504
Drug: ANTI-IGE THERAPY (XOLAIR)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
Study: NCT04459702
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with the drug azithromycin
Study: NCT01944046
Drug: Double blind phase Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
Study: NCT03848221
Drug: Sensitive Eyes Rewetting Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitive Eyes Rewetting Drops is a rewetting drop.
Study: NCT00904540
Drug: Lidoderm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
Study: NCT04276545
Drug: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
Study: NCT02264795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Solution
Study: NCT00399477
Drug: Rasagiline mesylate with Levodopa
Normalized name: Rasagiline Mesylate
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azilect®, Levodopa
Study: NCT02007577
Drug: salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
Study: NCT02007577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 3 tablets with breakfast and 4 tablets with dinner
Study: NCT01552044
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg tablet once a day for 1 month
Study: NCT01552044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet once a day for 1 month
Study: NCT02504294
Drug: IV Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
Study: NCT04351438
Drug: Active comparator: Filter TPE with citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received citrate-based anticoagulation with filter TPE
Study: NCT02532218
Drug: ARI-3037MO
Normalized name: OVIS ARIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering treatment Statins
Study: NCT00366626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 7 days matched to Naltrexone
Study: NCT00986999
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
Study: NCT02255175
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive transdermal estradiol (100μg/day) for 3 weeks
Study: NCT03998826
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg piroxicam
Study: NCT03998826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00935025
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple oral doses, extended-release capsule
Study: NCT00935025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple oral doses, capsule
Study: NCT00421499
Drug: dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02709954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study: NCT02709954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
Study: NCT02709954
Drug: Active Oral Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Study: NCT02542748
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norepinephrine injection
Study: NCT02268838
Drug: E6007 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01881308
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01881308
Drug: Co-medication: Synthetic DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
Study: NCT03650881
Drug: Neutrogena ® Light Therapy Acne Mask (MASK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
Study: NCT02427529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00951600
Drug: oxcarbazepine 300 mg/5mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01892748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
Study: NCT00550225
Drug: GSK961081
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
Study: NCT00550225
Drug: GSK961081 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
Study: NCT02101892
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os, daily, evening
Study: NCT00388414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill once daily
Study: NCT01156701
Drug: Receiving a prescription of Relenza for prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving a prescription of Relenza for prophylaxis
Study: NCT00288158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03910127
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT01253434
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2022 Type A patch
Study: NCT01253434
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2022 Type B patch
Study: NCT01253434
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2022 Type C patch
Study: NCT01253434
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2022 Type D patch
Study: NCT01253434
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2022 Type E patch
Study: NCT00690521
Drug: Treatment of Furosemide + Hydrochlorothiazide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
Study: NCT04321252
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)
Study: NCT04321252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placeo for iv administration
Study: NCT01426399
Drug: LC15-0444
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC15-0444 50mg qd (8 days once daily)
Study: NCT02848417
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Study: NCT01211626
Drug: ANA773
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANA773 Tosylate Capsule
Study: NCT01211626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Capsule
Study: NCT00139750
Drug: CP-526,555 (varenicline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01458574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg orally (PO) twice a day (BID)
Study: NCT01458574
Drug: CP690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 5 mg orally (PO) twice a day (BID)
Study: NCT01458574
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 10 mg orally (PO) twice a day (BID)
Study: NCT02506296
Drug: DPPIV inhibitor -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed Meal Tolerance Test with or without a DPPIV inhibitor
Study: NCT01951235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03164512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule/vapor
Study: NCT04032171
Drug: Avonex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received avonex® IM injection once a week.
Study: NCT04032171
Drug: Avonex® matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received IM injection of placebo matched to avonex® once a week.
Study: NCT00747799
Drug: Sorafenib plus Cisplatin and 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles
Study: NCT00497653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 6 weeks
Study: NCT00424437
Drug: Inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03743038
Drug: FMX101 vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
Study: NCT00411567
Drug: inhaled corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03843918
Drug: LAE001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
Study: NCT02302079
Drug: ASP8232
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02302079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT01503905
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2, iv injection, day1, every 21 days
Study: NCT01069523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
Study: NCT03820037
Drug: BIA 9-1067 (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
Study: NCT02504476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01503905
Drug: Cyclophosphamide (post-operative)
Normalized name: Sx1 Medicated Post-Operative System KIT
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.